Telegraph

7x24 real-time news feed, auto refreshBeijing Time：

All A·Important B·Normal #cell ✕
B
[CSPC Innovation: SYS6010 included in the list of breakthrough therapies] On September 1, CSPC Innovation (300765.SZ) announced that SYS6010, developed by the company's holding subsidiary Jushi Biologics, was included in the list of breakthrough therapies by the Drug Evaluation Center of the State Food and Drug Administration. The proposed indication is for patients with recurrent or metastatic head and neck squamous cell carcinoma who have failed immune and platinum-containing chemotherapy. SYS6010 is an antibody-drug conjugate targeting EGFR, and key Phase III clinical trials for this indication are currently underway. Previously, SYS6010 has received two breakthrough therapy designations, respectively for EGFR mutation-positive advanced non-small cell lung cancer and advanced esophageal squamous cell carcinoma.
#clinical trial#cell#A-share announcement express09-01 16:56
B
[CAR-T therapy significantly reduces the symptoms of severe rheumatoid arthritis] September 1st, Chimeric Antigen Receptor T-cell immunotherapy (CAR-T) is mainly used to treat cancer, but this type of personalized therapy prepared from the patient's own immune cells is also expected to be used for autoimmune diseases. German scientists reported the results of the world's first relevant clinical trial: After receiving CAR-T treatment, the symptoms of six patients with severe rheumatoid arthritis were significantly reduced, and three of them no longer needed any anti-rheumatic drugs at the end of the observation period. The relevant paper was published in the latest issue of Nature Medicine.
#clinical trial#medicine#cell#Global market intelligence09-01 07:11
A
[A hidden fibroblast is actually the "accomplice" of lung cancer] August 31st, a cell type that is difficult to detect may be hidden in lung cancer tissue. They are not cancer cells, but they can become "accomplices" to lung cancer and provide an "immune protective umbrella" for tumors. Researchers at Columbia University in the United States have discovered that this type of cells can recruit regulatory T cells to help lung cancer evade immune system attack. Relevant research was published in the new issue of Nature Immunology.
#immune system#Immunology#cell#Global market intelligence08-31 06:55
A
[Gene switch allows 3D printed bone tissue to grow new blood vessels autonomously] On August 31, an interdisciplinary team at Pennsylvania State University in the United States achieved a breakthrough: after programming cells, they used gene switch technology to allow 3D printed bone tissue to autonomously generate new blood vessels. This achievement brings new hope for the treatment of bone defects caused by severe trauma or infection. The relevant paper was published in the new issue of "Journal of Chemical Engineering".
#3D printing#Chemical#programming#Gene#cell#Global market intelligence08-31 06:54